|
|
Newsletter Index, Volume 1, 2007-2008 |
An index to brand-name drugs, generic drugs and health issues discussed in Drug Safety Newsletter articles. A list of drug safety alerts and communications can be found on the Index to Drug-Specific Information.
Page numbers refer to the print version (PDF).
A
- Acute Pancreatitis
- Exenatide, 12-14
- Adalimumab
- Serious Skin Reactions, 18-22
- Alimta, 30-32
- Amiodarone, 46-48
- Aplastic Anemia
- Temozolomide, 7-8
B
- Byetta, 12-14
C
- Carbamazepine
- HLA-B*1502, 35-37
- Stevens-Johnson Syndrome, 35-37
- Toxic Epidermal Necrolysis, 35-37
- Carbatrol, 35-37
- Cialis, 15-17
- Cordarone, 46-48
- Cymbalta, 22-24
D
- Deferasirox, 8-9
- Duloxetine, 22-24
E
- Enbrel, 18-22
- Equetro, 35-37
- Erythema Multiforme
- Lenalidomide, 43-46
- Etanercept
- Serious Skin Reactions, 18-22
- Exenatide
- Acute Pancreatitis, 12-14
- Exjade, 8-9
- Extraneal, 49
G
- Glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ), 49
- Glucose-dye-oxidoreductase (GDO), 49
H
- Hearing Loss
- PDE-5 Inhibitors, 15-17
- Sildenafil, 15-17
- Tadalafil, 15-17
- Vardenafil, 15-17
- HLA-B*1502
- Carbamazepine, 35-37
- Humira, 18-22
- Hypoglycemia
- Icodextrin, 49
I
- Icodextrin
- Extraneal, 49
- Infliximab
- Serious Skin Reactions, 18-22
L
- Lariam, 41-43
- Lenalidomide
- Serious Skin Reactions, 43-46
- Levitra, 15-17
M
- Medication Errors, 50-52
- Mefloquine Hydrochloride
- Pneumonitis, 41-43
- Modafinil
- Serious Skin Reactions, 5-7
N
- Natalizumab
- Serious Liver Injury, 33-35
P
- Pacerone, 46-48
- PDE-5 Inhibitors
- Hearing Loss, 15-17
- Pemetrexed
- Radiation Recall, 30-32
- Pharmacogenomics, 24-26
- PML (Progressive Multifocal Leukoencephalopathy), 3-5
- Pneumonitis
- Mefloquine Hydrochloride, 41-43
- Progressive Multifocal Leukoencephalopathy (PML), 3-5
- Provigil, 5-7
R
- Radiation Recall
- Pemetrexed, 30-32
- Remicade, 18-22
- Revatio, 15-17
- Revlimid, 43-46
- Rhabdomyolysis
- Amiodarone, 46-48
- Simvastatin, 46-48
- Zocor, 46-48
- Vytorin, 46-48
- Simcor, 46-48
- Cordarone, 46-48
- Pacerone, 46-48
- Rituxan, 3-5
- Rituximab
- Progressive Multifocal Leukoencephalopathy (PML), 3-5
S
- Serious Liver Injury
- Natalizumab, 33-35
- Serious Skin Reactions
- Adalimumab, 18-22
- Etanercept, 18-22
- Infliximab, 18-22
- Lenalidomide, 43-46
- Modafinil, 5-7
- TNF-α Antagonists, 18-22
- Sildenafil
- Hearing Loss, 15-17
- Simcor, 46-48
- Simvastatin, 46-48
- Stevens-Johnson Syndrome
- Carbamazepine, 35-37
- Lenalidomide, 43-46
T
- Tadalafil
- Hearing Loss, 15-17
- Tegretol, 35-37
- Temodar, 7-8
- Temozolomide
- Aplastic Anemia, 7-8
- TNF-α Antagonists
- Serious Skin Reactions, 18-22
- Toxic Epidermal Necrolysis
- Carbamazepine, 35-37
- Lenalidomide, 43-46
- Tysabri, 33-35
V
- Vardenafil
- Hearing Loss, 15-17
- Viagra, 15-17
- Vytorin, 46-48
Z
- Zocor, 46-48
|